Arrhythmia Research Technology, Inc.  

(Public, NYSEMKT:HRT)   Watch this stock  
Find more results for NYSEAMEX:HRT
0.00 (-0.10%)
Feb 10 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 4.36 - 4.50
52 week 4.17 - 7.73
Open 4.50
Vol / Avg. 400.00/3,684.00
Mkt cap 12.15M
P/E     -
Div/yield     -
EPS -0.14
Shares 2.79M
Beta 0.86
Inst. own 11%
Mar 18, 2016
Q4 2015 Arrhythmia Research Technology Inc Earnings Release (Estimated) Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -5.08% 2.75%
Operating margin -3.87% 3.70%
EBITD margin - 10.10%
Return on average assets -6.93% 4.20%
Return on average equity -14.51% 9.73%
Employees 98 -
CDP Score - -


25 Sawyer Passway
United States - Map
+1-978-3455000 (Phone)
+1-978-3420168 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Arrhythmia Research Technology, Inc. is a contract manufacturing organization (CMO). Through its wholly owned subsidiary, Micron Products, Inc., the Company produces medical device technologies requiring precision machining and injection molding. The Company also manufactures components, devices and equipment for military, law enforcement, industrial and consumer product applications. It is a manufacturer and distributor of silver-plated and non-silver plated conductive resin sensors for use in the manufacture of disposable electrodes for electrocardiogram (ECG) diagnostic, monitoring and related instrumentation. The Company is also a contract manufacturer of orthopedic implant components for full and partial knee replacements, including femorals, tibial trays and inserts with capabilities. Its plastic injection molding services are suited to consumable medical products and medical device components.

Officers and directors

E. P. Marinos Independent Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Salvatore Emma Jr. President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Derek T. Welch Chief Financial Officer
Age: 46
Bio & Compensation  - Reuters
Bryan S. Ganz Director
Age: 51
Bio & Compensation  - Reuters
Robert A. Mello Director
Age: 61
Bio & Compensation  - Reuters
.. S. .. Independent Director
Age: 51
Bio & Compensation  - Reuters
Marco F. Benedetti Independent Director
Age: 56
Bio & Compensation  - Reuters
Jason R. Chambers Independent Director
Age: 37
Bio & Compensation  - Reuters